NDC properties for NDC 9 51759-311
NDC item 51759031158
| NDC 9 | 51759-311 |
|---|---|
| NDC 10 | 51759-311-58 |
| NDC Item | 51759031158 |
| packaging | 1 KIT in 1 CARTON (51759-311-58) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .8 mL in 1 SYRINGE (51759-313-30) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2026-05-01 |
| Marketing status | active |
NDC item 51759031330
| NDC 9 | 51759-313 |
|---|---|
| NDC 10 | 51759-313-30 |
| NDC Item | 51759031330 |
| packaging | 0.8 mL in 1 SYRINGE |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG LABEL |
NDC item 51759036117
| NDC 9 | 51759-361 |
|---|---|
| NDC 10 | 51759-361-17 |
| NDC Item | 51759036117 |
| packaging | 1 KIT in 1 CARTON (51759-361-17) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .8 mL in 1 SYRINGE * .4 mL in 1 POUCH |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2025-07-01 |
| Marketing status | ACTIVE |
NDC item 51759036921
| NDC 9 | 51759-369 |
|---|---|
| NDC 10 | 51759-369-21 |
| NDC Item | 51759036921 |